EUVIMEDEUVIMED entdecken
Fallbericht

Demyelinating polyradiculoneuropathy during dabrafenib and trametinib treatment for metastatic melanoma: A case report

Marta Venturelli, Stefano Greco iD, Cinzia Baldessari iD, Giuseppe Pugliese, Roberta Depenni, Massimo Dominici

Tumori Journal · 2023

DOI: 10.1177/03008916231202102 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Tumori Journal, 2023. Verfasst von Marta Venturelli und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Haematology, University Hospital of Modena, Modena, Italy. Hauptthemen laut MEDLINE: Melanoma, Polyradiculoneuropathy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Melanoma is an aggressive malignancy, historically characterized with a poor prognosis and few treatment options. The advent of target therapy with BRAF and MEK inhibitors, as well as immunotherapy, changed this scenario and improved the prognosis of patients with BRAF V600E mutation. These therapies are generally well tolerated. Neurological toxicities, especially polyradiculopathy, are very rare with BRAF inhibitors and MEK inhibitors although some cases have been described in recent years, regardless of the type of target therapies combination used. Case report: We report the case of a patient with BRAF V600E-mutated metastatic melanoma treated with dabrafenib and trametinib who has developed a demyelinating polyradiculoneuropathy.

Conclusion

This case, once more, should draw our attention to the possibility of rare, but potentially serious side effects, even in the case of generally well-tolerated treatments. Especially in the presence of side effects, it is important a close relationship between clinicians and patients for the management of adverse events and the choice of the best treatment strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaPolyradiculoneuropathyHumansProto-Oncogene Proteins B-rafPyridonesMitogen-Activated Protein Kinase KinasesAntineoplastic Combined Chemotherapy ProtocolsMutationImidazolesOximesPyrimidinones

Stichwörter der Autor:innen

Dabrafenibmelanomaneurological toxicitypolyradiculoneuropathytarget therapytrametinib

Substanzen

Proto-Oncogene Proteins B-rafPyridonesMitogen-Activated Protein Kinase KinasesdabrafenibImidazolesOximestrametinibPyrimidinones

Autor:innen und Institutionen

  • Department of Oncology and Haematology, University Hospital of Modena, Modena, Italy.

ORCID-Profile: Stefano Greco, Cinzia Baldessari

Zitieren

APA

Venturelli, M., Greco, S., Baldessari, C., Pugliese, G., Depenni, R., & Dominici, M. (2023). Demyelinating polyradiculoneuropathy during dabrafenib and trametinib treatment for metastatic melanoma: A case report. Tumori Journal. https://doi.org/10.1177/03008916231202102

Vancouver

Venturelli M, Greco S, Baldessari C, Pugliese G, Depenni R, Dominici M. Demyelinating polyradiculoneuropathy during dabrafenib and trametinib treatment for metastatic melanoma: A case report. Tumori Journal. 2023. doi:10.1177/03008916231202102

BibTeX
@article{Venturelli2023,
  author = {Venturelli, Marta and Greco, Stefano and Baldessari, Cinzia and Pugliese, Giuseppe and Depenni, Roberta and Dominici, Massimo},
  title = {Demyelinating polyradiculoneuropathy during dabrafenib and trametinib treatment for metastatic melanoma: A case report},
  journal = {Tumori Journal},
  year = {2023},
  doi = {10.1177/03008916231202102}
}
Kostenlos starten →